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Molecular Epidemiology in Cancer Risk
Assessment and Prevention: Recent Progress
and Avenues for Future Research
by Gerald N. Wogan
Molecular epidemiology is increasingly being applied in studies of cancer risks derived from exposure to
environmental carcinogens ofboth endogenous and exogenous origins. Analytical methods have been devel-
oped that are capable ofdetecting and quantifying levels ofcovalent adducts of several important classes of
carcinogens with cellular DNA and blood proteins. Methods of sufficient sensitivity and specificity to detect
ambientlevels ofexposure are incurrentuse. Thesearebeingused in studiesrelatedtotobacco use (polycyclic
aromatic hydrocarbons, aromatic amines, tobacco-specific nitrosamines); dietary exposures (aflatoxins,
N-nitrosamines, heterocyclic amines); medicinal exposures (cisplatin, alkylating agents, 8-methoxypsoralen,
ultraviolet photoproducts); occupational exposures (aromatic amines, polycyclic aromatic hydrocarbons,
oxides ofethylene andstyrene, andvinyl chloride); andoxidative damage (8-hydroxyguanine, thymineglycol).
Methodologic improvements together with their expanded use in feasibility studies continue to produce
results that support the validity of this approach for detecting and quantifying exposure to carcinogens.
Genetic markers are alsobeingusedtodetectearlybiological responses ineffortsto linkcarcinogen exposure
toinitiatingeventsinthecarcinogenesisprocess.Theseinclude,inadditiontotraditional cytogeneticmarkers
(e.g., chromosomal aberrations, sister chromatid exchange, micronuclei), other alterations in chromosomal
structure such as restriction fragment length polymorphisms, loss of heterozygosity, and translocation
markers. Specific genetic changes have recently been identified as critical molecular events in the initiation
anddevelopmentofmanycancers. Important amongthese are activation ofoncogenes, especiallythose ofthe
ras family, and inactivation oftumor-suppressor genes (e.g.,p53 andRb) bypointmutations and/or chromoso-
maldeletionsandotherstructural changes.Although someofthesechanges areknowntooccurinchemically
induced tumorsofexperimental animals, thepossible role ofchemical carcinogens in the induction ofgenetic
abnormalities inhumancancershasyettobedetermined. Continuinginvestigations employingthemethodsof
molecular epidemiologypromise to provide furtherevidence concerningthese relationships. Future investiga-
tionsemployingnewlydeveloped molecularbiological methods, inparticularthosebased onpolymerase chain
reaction amplification of DNA, to identify alterations in DNA and chromosomal structure, combined with
methods for characterizing exposure to carcinogens and early effects, have great potential for further
elucidating the role of genotoxic agents in the etiology of human cancers and also for the development of
strategies for their prevention.
Introduction
Molecular epidemiology of cancer involves the use of
biomarkers of exposure and response in studies of ex-
ogenous or endogenous agents and/or host factors that
play arolein human canceretiology. The approach has the
potential for serving multiple purposes, including im-
proved accuracy of exposure measurement, identification
ofsusceptible individuals in the presence ofadVerse expo-
sures, detection ofsubclinical disease, more homogeneous
classifications ofdisease, increased knowledge ofdisease
pathogenesis, and improvements in methodology for pre-
ventive and therapeutic trials (1). As laboratorymethodol-
ogy for detection of exposure and response markers has
advanced, the applications ofmolecularepidemiology have
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concomitantlyincreased in numberandlevel ofsophistica-
tion. Progress over the past 5 years, which is the time
frame encompassed by information discussed here, has
been substantial. The field has been the subject of many
symposia, workshops, and other meetings, and various
aspects have also been extensively reviewed (e.g., 1-8). In
addition, many facets ofthe field are discussed more fully
in other papers in this volume.
Atthepreviousmeetingofthis series, heldinHelsinkiin
1987, themajorfocus ofdiscussionwasmethods for detec-
tion and characterization of genotoxic agents and their
application in detection and prevention ofhuman cancers.
At that time, analytical procedures were available for
detection and quantification of adducts formed between
DNA or blood proteins and genotoxic carcinogens of a
variety of structural types. In the intervening period,
many of these have been modified to make them more
sensitive, accurate, and easy. Methods for additionalG. N. WOGAN
classes of carcinogen-DNA and -protein adducts have
also been developed, and the list ofcarcinogen adducts for
which analytical methods are available is now quite sub-
stantial. Methods ofsufficientsensitivityand specificityto
detectambientlevels ofexposure arein currentuse. These
are being used in studies of tobacco use (polycyclic aro-
matic hydrocarbons [PAH], aromatic amines, tobacco-
specific nitrosamines); dietary exposures (aflatoxins,
N-nitrosamines, heterocyclic amines); medicinal expo-
sures (cisplatin, alkylating agents, 8-methoxypsoralen,
ultraviolet photoproducts); occupational exposures (aro-
matic amines, PAH, oxides of ethylene and styrene, and
vinyl chloride); and oxidative damage (8-hydroxyguanine,
thymine glycol). Methodologic improvements, together
with their expanded use in feasibility studies, continue to
produce results that support the validity ofthis approach
for detecting and quantifying exposure to carcinogens,
andinvestigations designedtotesttheirabilitytomeasure
exposures associated with elevated cancer risks are being
conducted in increasing numbers.
Over the same interval oftime, information concerning
genetic alterations in cancers has increased significantly.
Ofparticular relevance to molecular epidemiology are the
geneticmarkers thatarealsobeingemployedfordetection
ofearly biological responses, in efforts to link exposure to
carcinogens to initiating events in the carcinogenesis pro-
cess. These include, in addition to traditional cytogenetic
markers (e.g., chromosomal aberrations, sister chromatid
exchange, micronuclei), other alterations in chromosomal
structure such as restriction fragment length polymor-
phisms, loss ofheterozygosity, and translocation markers.
Specific genetic changes have recently been identified as
critical molecular events in the initiation and development
ofmany cancers. Important amongthese are activation of
oncogenes, especiallythose ofthe rasfamily, and inactiva-
tion oftumor-suppressor genes (e.g., p53 and Rb) bypoint
mutations and/or chromosomal deletions and other struc-
tural changes. Although some ofthese changes are known
to occur in chemically induced tumors of experimental
animals, the possible role of chemical carcinogens in the
induction of genetic abnormalities in human cancers has
yettobe determined. Continuinginvestigations employing
the methods ofmolecular epidemiologypromise toprovide
further evidence concerning these relationships.
Increased attention has been given to the importance of
host susceptibility factors as determinants of individual
cancerrisk, in addition tomarkers ofexposure andbiolog-
ical response, and substantial research effort has been
devoted to developing markers of susceptibility. These
include polymorphisms ofcarcinogen metabolism, ofboth
genetic and environmental origin, which involve both
activation and inactivation pathways. Markers for poly-
morphisms in activation pathways entail measurement of
activity of members of the cytochrome P450 family of
monooxygenases and of conjugating enzymes including
glutathione-S-transferases, acetyltransferases, sulfo-
transferases, glucuronyltransferases and peroxidases.
Markers of genetic polymorphisms in drug metabolism
have also been developed and are being evaluated with
respect to their relationships to cancer risks. These
include,forexample, theabilitytometabolizedebrisoquine
(the CYP2D6 locus) and transcriptional activation by
2,3,7,8-tetrachlorodibenzo-p-dioxin (the CYPlAl locus).
The importance of inherited predisposition has also
become increasingly evident as detailed genetic analyses
have been done on specific geneticallylinked cancers such
as retinoblastoma, Wilms' tumor, familial adenomatous
polyposis, and the Li-Fraumeni syndrome. The impor-
tance ofDNArepairdeficiency, e.g.,inxerodermapigmen-
tosum, as an inherited factor that predisposes individuals
to elevated cancer risk has long been known.
The conceptual basis for the way in which molecular
epidemiology can indicate the mechanisms on the basis of
which these classes ofmarkers have been developed, and
themannerinwhichtheyarerelated tothe carcinogenesis
process, are summarized in Figure 1. This diagram illus-
trates the mechanistic paradigm of chemically induced
carcinogenesis, on the basis of current knowlege of the
process, in which exposure to chemical carcinogens leads
to their absorption, metabolic activation, and subsequent
covalent binding to cellular DNA and proteins. Measure-
mentofDNAandprotein adductsis designedto serve as a
marker of exposure and biologically effective dose. The
pattern ofDNAadducts thus formed can be substantially
altered by repair processes of varying efficiency and
fidelity with respect to different carcinogens, tissues, and
cell types. Replication of carcinogen-modified DNA is
thought to result in the fixation ofmutations that serve as
initiating events in transformation. These can be detected
throughtheuseoftraditional cytogeneticmarkers such as
sister chromatid exchange or micronuclei in peripheral
white blood cells (WBC), or through the detection of
mutations at specific genetic loci, including hprt, HLA, or
glycophorin in WBC and red blood cells. Mutations in the
ras and p53 genes can also be detected in the cells ofend-
stage tumors, where they are thought to be of functional
significance in tumorigenesis. Increased cell proliferation,
with clonal expansion of cells containing mutations that
impartgrowth advantages is accompanied bythe accumu-
lation of further genetic alterations, such as additional
point mutations, gene amplification, translocations, allelic
loss, and chromosomal deletions. The number of genetic
changesinvolvedis notknown, assuggestedbythedashed
arrows in the diagram.
Much of the information about molecular biomarkers
that has accumulated in the recent past relates to the
earliestandlateststages oftheprocess,i.e.,biomarkers of
exposureandbiologicallyeffectivedose,andbiomarkersof
altered structure and function or ofclinical disease. In the
latter category, mutations that cause activation of ras
oncogenes and inactivation of the p53 gene have been
detected in tumors of diverse types and at varying fre-
quencies. Certain relevant aspects ofthis information are
summarized in subsequent sections. The nature of the
mutations has supported the conjecture that they could
have been induced by exposure to chemical carcinogens,
but direct evidence ofthat relationship does not yet exist.
The discovery of mutated ras and p53 genes in a high
proportion of adenomatous polyps representing early
stages ofcolon cancer suggests that analyticalmethods of
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FIGURE 1. Conceptual basis for the development ofbiomarkers for use in molecular epidemiology. SCE, sister chromatid exchange.
adequate sensitivity may make it possible to detect such
mutations in the early stages of other forms of cancer,
including those associated with chemical exposures, and
thus serve as markers of early biological effect. Little
direct information is currently available, however, to sup-
port the conjecture that mutations observed in oncogenes
or tumor-suppressor genes in end-stage tumors or in
preneoplastic cells in humans are induced by carcinogens.
Several investigators have sought to address this issue
through the study ofmutations induced at speciflc loci in
the DNA of accessible surrogate cells in cancer chemo-
therapypatients exposedtolarge doses ofgenotoxic drugs
orionizingradiation. Theresults ofsuch studies,which are
summarized below, provide interestingandimportant per-
spectives on the use of the techniques of molecular epi-
demiology to detect and quantify genotoxic exposures.
DNA and Protein Adducts in Detection
of Genotoxic Exposures
Analytical methods are now available for the detection
and quantification of covalent adducts formed between
DNA and proteins and genotoxic chemicals. Methods for
DNA adduct analysis include immunoassays, 32P-post-
labeling, and physicochemical procedures, the latterbeing
based on suchproperties asfluorescence orinvolving mass
spectrometry (MS) and electrochemical analysis. Protein
adducts in hemoglobin (Hb) and serum albumin can be
analyzed by physicochemical methods, principally gas
chromatography (GC)-MS, or by immunoassay. Collec-
tively, methods are now available for the detection ofDNA
and/or protein adducts of many of the major classes of
chemical carcinogens. These include PAH, particularly
benzo[a]pyrene diol epoxide (BPDE), aromatic amines,
nitrosamines of several types, aflatoxins, heterocyclic
amines, medicinal agents of several classes, industrial
chemicals (styrene and ethylene oxide), and products of
oxidative DNAdamage. These analytical procedures have
been applied in studies of human populations exposed to
genotoxic chemicals under a variety of circumstances.
Space does not permit comprehensive review of this sub-
ject, but the following summary ofrecentpublications will
serve to indicate the directions these investigations have
taken and the nature of findings obtained to date. For
convenience, this information is grouped according to
sources and types of exposure, including tobacco use,
dietary, medicinal, and occupational exposures, and oxida-
tivedamage.
Adducts in White Blood Cell DNA and
Blood Proteins
Manyinvestigators have directed their efforts to detec-
tion ofDNAandprotein adductsin smokers orother users
of tobacco. In a substantial fraction of these studies
peripheral WBC were used as a source of DNA for anal-
ysis.Analysis by32P_postlabeling revealed the presence of
multiple adducts in the WBC DNA of smokers, with total
concentrations of one adduct in 108_1010 normal nucleo-
tides (9). In another investigation using the same analyti-
calprocedure, the meannumberofWBC DNAadducts per
10i nucleotides in smokers (31 + 5.7) was significantly
larger than that in nonsmokers (13 + 1.6) (10). In a study
designed to compare PAH-DNA adduct levels (measured
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by enzyme-linked immunosorbent assay [ELISA]) with
the frequency of sister chromatid exchange in peripheral
WBC of lung cancer cases and control subjects, DNA
adduct levels were not significantly related to active or
passive cigarette smoking, nor to age, sex, ethnicity, or
otherparameters (11).
In a study ofthe association ofHb adducts of15 amines
with smoking status and type oftobacco smoked, levels of
the 4-aminobiphenyl adduct varied significantly between
nonsmokers and smokers ofblond and black tobacco (12).
Subsequently, itwasfoundthatlevels of4-aminobiphenyl-
Hb adducts were related not onlyto tobacco type,_butalso
toacetylationphenotype,withadductlevelsbeingelevated
in slowacetylators (13). Levels ofthe4-aminobiphenyl-Hb
adduct were also found to decline in the blood ofsmokers
enrolledin awithdrawal program, decreasingfromamean
of120 ± 7pg/g Hb to 34 ± 5 pg/g after 2 months (14). Hb
adducts of 4-aminobiphenyl have also been detected in
fetuses exposed to tobacco smoke in utero, indicating that
the carcinogen or its active metabolite, N-hydroxy-4-
aminobiphenyl, crosses the human placenta, and binds to
fetal Hb in concentrations that arehigherin smokers than
nonsmokers (15). MS has been used in the analysis of
tobacco-specific nitrosamine-Hb adducts in smokers, non-
smokers, and snuff dippers. Mean adduct levels (fmole
4-hydroxy-1-(3-pyridyl)-1-butanone/g Hb) were 517 ± 538
in snuffdippers, 79.6 ± 189in smokers, and 29.3 ± 25.9 in
nonsmokers (16). These results are the first reported
measurements of tobacco-specific nitrosamine-Hb ad-
ducts in humans and indicate the potential usefulness of
the analytical procedure for further characterization of
cancer risks associated with cigarette smoking.
Analysis of DNA and protein adducts has also been
successfully employed in the detection and quantification
of exposure through dietary contamination by several
carcinogens, including aflatoxins and PAH. Methods of
several types have been employed for the detection of
aflatoxin-serum albumin adducts. Levels of the aflatoxin
Bl-albumin adduct detected by competitive radioim-
munoassay were found to correlate well with aflatoxin
ingestion, aswell aswith urinaryexcretion ofthe metabo-
lite aflatoxin M1 (17). A similar correlation between
aflatoxin ingestion and albumin adductlevel was obtained
through application of an analytical method combining
immunoaffinity chromatography and high-performance
liquid chromatography (HPLC) for detection and quan-
tification of the aflatoxin Bl-lysine adduct isolated from
serum albumin (18). Asimilarmethod hasbeen devisedfor
analysis of the aflatoxin G1-lysine adduct (19), which will
be useful in further studies of exposure to aflatoxins in
human populations. An immunoassay (ELISA) method
has also been used in a survey ofaflatoxin to exposure in
different regions oftheworld, which showed that 12-100%
of children and adults in various African countries have
aflatoxin-serum albumin adducts, with levels ofup to 350
pg aflatoxin Bl-lysine equivalent/mg albumin (20).
Aflatoxin adducts were also detectedbyimmunoassayand
HPLC in DNAfrom human tissues after an acute poison-
ing incident in Southeast Asia (21).
An investigation of the effect of ingestion of large
amounts of charcoal-broiled beef on formation of PAH
adductsinperipheralWBC, detectedbyELISA, showed a
3- to 6-fold elevation in the level ofadducts in two offour
subjects following a1-weekperiod ofingestion (22). These
resultsindicatethatdietarysourcesofPAHcancontribute
to the PAH-DNA adduct levels in WBC of some indi-
viduals. Methods for detecting DNA or protein adducts
with other known dietary carcinogens are not yet avail-
able; however, two recent reports indicate progress in the
development of such methods for the heterocyclic amine
2-amino-3,8-dimethylimidazo[4,5-flquinoxaline (MeIQx). A
GC-MS method capable of detecting the parent amine
liberated from Hb after hydrolysis was employed in the
investigation of the covalent binding of 14C-MeIQx to
mouseHbinvivoandinvitro(23).Althoughbindingofthe
radioactive amine to Hb was demonstrable at relatively
highdoses, the analyticalmethodwas capable ofdetecting
binding only at the highest doses used, and application of
the GC-MS method to human Hb showed that if any
MeIQx adducts were present the levelwas belowthe limit
ofdetectionoftheassay(2fmoleMeIQx/mgHb).Thus,the
abilitytodetectexposuretothisimportantclassofdietary
carcinogensawaitsdevelopmentofnewanalyticalmethods
ofgreater sensitivity.
Studies ofDNAand protein adducts in patients treated
withdrugsthatdamageDNA,inparticularcancerchemo-
therapeutic agents, have been veryinformative, inasmuch
as the dose levels are known and are higherthan environ-
mental exposures. Several such studies have been con-
ducted on patients treated with cisplatin, for which
immunoassays are available for the quantification ofDNA
adducts in WBC and tumor tissue DNA. Earlier studies
showed that the extent ofplatinum-DNA adduct levels in
WBC of ovarian cancer patients was directly related to
disease response. Recently, a similar correlation between
cisplatin-DNA adduct formation in peripheral WBC and
disease response has been shown in patientswith testicu-
lar cancer and a poor prognosis (24). Further, in a small
cohort ofrefractory ovarian cancer patients treated with
cisplatin or carboplatin, the adduct level in WBC DNA
appeared to be more closely related to disease response
than any previously identified prognostic variable (25). In
another study of similar design (26), a nonlinear depen-
dence of adduct levels on total dose of cisplatin was
observed, which was attributed to removal of adducts.
Within 21 hr ofthe first cisplatin infusion, 76% ofadducts
were removed, indicating the potential importance ofthis
variable in the interpretation of adduct levels obtained in
single blood samples collected in the course ofbiomonitor-
ing studies. It is important to note, however, that adduct
levels determined by ELISA do not agree well with those
obtained byatomic absorption spectroscopy, andtherefore
the basis of the relationship between adduct levels and
clinical response is still unclear.
Products ofDNA alkylation have also been detected in
WBC DNA ofpatients undergoing cancer chemotherapy.
06-Methylguanine was detected in the WBC DNA of
lymphoma patients receiving procarbazine, with levels
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accumulating throughout the exposure period (27). Simi-
larly, leukocyte DNA from blood of patients with Hodg-
kin's diseasereceivingatherapeutic regimenthatincluded
dacarbazine was found to contain 06-methylguanine at
levels ranging up to 0.45 fmole/,ug DNA (28). The average
extentof06-methylguanineformation 1 hraftertreatment
was 4.3 x 10-2 fmole/,ug DNAper mg/kg dose. Recently,
a32P-postlabelingmethodwasdevelopedtomeasurelevels
of 7-methylguanine in WBC DNA, and its application to
the blood ofhealthy nonsmokers revealed the presence of
7-methylguanine at an average level of 2.5 residues/107
nucleotides (29). In cancer patients receiving dacarbazine
or procarbazine at total doses of 1050-2800 mg, the
observed mean adduct level was 57 residues/107 nucleo-
tides. This method was suggested as that most suited to
postlabeling of large and labile 7-alkylguanines in DNA.
DNA and protein adducts have been determined in
patients treated with additional therapeutic regimens. An
immunofluorescence assay involving a monoclonal anti-
body that recognizes 8-methoxypsoralen photoadducts
was used to analyze DNA isolated from skin biopsies of
psoriasis patients treated with 8-methoxypsoralen and
ultraviolet Alight. Adducts were detected in DNA ofskin
biopsies, but an ELISA using the same monoclonal anti-
body failed to detect adducts in the DNA of peripheral
WBC (30). Hydroxyethylation ofHb was detected by GC-
MS in the blood of patients treated with 1-(2-chloro-
ethyl)-1-nitrosoureas, suggesting that measurement of
(hydroxyethyl)valine in Hb may be a suitable monitor of
exposure to hydroxyethylating agents during (chloroeth-
yl)nitrosourea chemotherapy (31). Chromosomal altera-
tions inWBC, urinarymutagenicity and excretion ofPAH
metabolites were studied in psoriatic patients undergoing
coal-tar therapy (32): the results suggested that urinary
mutagenicity levels as well as frequencies of sister chro-
matid exchange and chromosomal aberrations were re-
lated to the levels ofexposure to coal tar.
Biological monitoring through the measurement of
DNAand protein adducts has also been applied in relation
to occupational exposuresunderavarietyofconditions. In
one such study, sisterchromatid exchange and PAH-DNA
adducts in peripheral blood cells were investigated in
firefighters (33). These subjects had a significantlyhigher
risk of detectable BPDE-DNA adducts than matched
controls, with tobacco smoking and consumption of
charcoal-broiled food and alcohol exerting confounding
effects on both parameters studied. Coke-oven workers
are occupationallyexposed torelativelyhighlevels ofPAH
and are atincreased risk oflung cancer. Analysis ofWBC
DNA for PAH adducts revealed that 47% ofworkers had
detectable levels of PAH-DNA adducts in their WBC, in
comparison to 30% of controls (34). In both groups,
smokershadsignificantlyhigherlevelsofadductsthandid
nonsmokers, but generally the correlation was not signifi-
cant between PAH-DNA adducts in blood and the con-
centration ofPAH in air orof1-hydroxypyrene inurine. In
another study of coke-oven workers and of residents of
towns near cokeries, it was found that PAH-DNA adduct
levels inWBC, determined by32P-postlabeling or ELISA,
were similar in coke-oven workers and local residents but
were two to three times lower in residents ofrural areas
(35). Furthermore, the results of this study showed that
the levels of adducts in WBC DNA were not related
linearly to ambient air levels of PAH, but other sources
such as food may have been important contributors. Alu-
minum production plant workers are similarly exposed to
high levels of PAH and may also be at increased risk of
lung and bladder cancer. Analysis ofWBC DNA for PAH
adductsby32P-postlabelingrevealed adductlevels ofupto
7.1 adducts per 108 nucleotides in exposed individuals,
comparedtolevelsofupto2.42adductsper108 nucleotides
incontrols (36). HigherDNAadductlevelswereassociated
with elevated levels of exposure in two plants of different
design.
Hb adducts have alsobeenused to monitoroccupational
exposures in two recent studies. HPLC combined with
synchronousscanningfluorescence spectroscopyprovided
a highly specific method for detecting covalently bound
benzo[a]pyrene residues in both Hb and DNA in blood of
coke-oven workers and in tissues from lung cancer
patients (37). A GC-MS method for detecting Hb adducts
with arylamines derived from urea and carbamate
pesticides hasrecentlybeendevised andvalidated in experi-
mental animals; this may provide a means of monitoring
occupational exposure to potentially hazardous components
ofpesticides (38).
The postulated importance of endogenously produced
oxidative DNA damage in cancer has prompted efforts to
develop methods that measure this damage. Earlier
methods were based on measurement of thymine glycol
and thymidine glycol in urine by HPLC, or of 8-hy-
droxy-2'-deoxyguanosine by HPLC with electrochemical
detection. Immunoaffinity isolation of 8-hydroxy-2'-de-
oxyguanosine and -guanine from urine and quantification
of the deoxyguanosine in DNA by polyclonal antibodies
have recently been reported (39). The immunoaffinity
procedurefacilitatedquantification oftheurinaryproduct,
and the same antibody preparation was used to quantify
8-hydroxy-2'-deoxyguanosine levels inhydrolysates ofcel-
lularDNAwithvaluescomparabletothoseobtainedbythe
earlier HPLC-electrochemical detection method. Quan-
tification of levels of an oxidation product of thymine,
5-hydroxymethyluracil, in WBC DNA has been used to
evaluate the relationship ofdietary fat level and oxidative
DNAdamageinwomen athighriskforbreastcancer (40).
Levels of 5-hydroxymethyluracil were linearly related to
dietary fat levels, and were 3-fold lower in a low-fat diet
group than in controls. These results suggest that oxida-
tive damage to DNAmaybe ausefulmarkerofdietaryfat
intake.
Adducts inTargetTissue and
Surrogate Cellular DNA
Interpretation ofadduct levels inWBC DNAin relation
totheirimplications forcancerriskentailsthe assumption
thatthese arevalid surrogates forDNAdamageincells of
target tissues. In order to circumvent this assumption,
increasing numbers ofstudies have focused on analysis of
adduct levels in cellular DNA ofputative target tissues. A
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pilot study was conducted to determine whether a spec-
trum of adducts of varying chemical structures could be
detected in small amounts ofhuman DNA (41). Peripheral
lung tissue was obtained at autopsy from trauma victims
with known occupational and smoking histories, and dif-
ferent carcinogen-DNA adducts were detected by use of
variety of sensitive analytical procedures. The results
indicate that human lung contains a broad spectrum of
carcinogen-DNA adducts and that molecular dosimetry
studies should encompass both aryl and alkyl chemical
carcinogens. Several studieshavesoughtto correlate DNA
adduct levels in human lungwith cigarette smoking. Mea-
surement oftotal adductlevelsby3'P-postlabeling in DNA
of lung tissue revealed that smokers had higher levels of
adducts than nonsmokers, thatthere was alinearrelation-
shipbetween adductlevels andcigarette consumption, and
also that adduct levels declined in subjects who stopped
smoking for 5 years to levels similar to those of non-
smokers (42). Subsequent studies of similar design, but
with confirmational quantification of PAH-DNA adduct
levels by ELISA, gave similar results and also showed a
positive, linearcorrelationbetween DNAadductlevels and
arylhydrocarbon hydroxylase activityinmicrosomes from
the same tissues (43,44). These findings were extended in
another investigation in which the tissue distribution of
putative DNA adducts was investigated by 32P-post-
labeling; it was found that DNA adducts derived from
smoking were present in kidney, bladder, esophagus,
aorta, and liver, but levels were highest in lung and heart
(45).AGC-MSmethodsimilartothatdescribedearlierfor
analysis ofHb adducts hasbeendevised to detecttobacco-
specific nitrosamine adducts of DNA (46). Analysis of
DNA from peripheral lung and tracheobronchial tissue
collected at autopsy revealed higher levels of 4-hydroxy-
1-(3-pyridyl)-1-butanone in both tissues from smokers
than in those from nonsmokers and indicated the useful-
ness of this method for providing increasingly accurate
information concerning DNAdamageresultingfrom ciga-
rette smoking. A further study was designed to investi-
gate the feasibility of measuring DNA-carcinogen
adducts in the lungs of nonsurgical patients (47). Endo-
bronchial biopsies were obtained from patients undergo-
ing routine bronchoscopy, and DNA isolated from them
was analyzed for adducts by HPLC or 32P-postlabeling,
using a procedure selective for aromatic adducts. Adduct
levels were found to be strongly associated with cigarette
smokinghistoryand with alcohol intake, but notwith lung
cancer independent of smoking history. The results fur-
ther indicated the feasibility of this approach for bio-
monitoringgeneticdamageinbronchialepithelium. Tissue
obtained through diagnostic bronchoscopy has also been
used to evaluate the detection ofmicronuclei as an indica-
tor of chromosomal damage resulting from cigarette
smoking(48). Thefindings obtained suggested thatmicro-
nuclei are a readily quantified, early-intermediate end
point for detecting tobacco-initiated tracheobronchial car-
cinogenesis. Analysis of adduct levels in exfoliated oral
mucosacellshas alsobeenexplored as a means ofmonitor-
ing exposure of the oral cavity to genotoxic agents, with
results leading to the conclusion that further improve-
ments in adduct identification will be needed for 32p-
postlabelingto be ausefultoolformonitoring exposureby
this route (49,50).
Analysis of DNA from biopsy samples ofurinary blad-
der by 32P_postlabeling was used to determine the preva-
lence of carcinogen-DNA adducts in relation to cigarette
smoking (51). Totalmean adductlevels andthemeanlevels
of several specific adducts were significantly higher in
current smokers than in nonsmokers or ex-smokers. One
ofthe specific adducts presentathigh levelswasidentified
as N-(deoxyguanosin-8-yl)-4-aminobiphenyl, confirming
the association between cigarette smoking and DNA
damage andsuggestingamolecularbasisfortheinitiation
ofbladder cancerbycigarette smoke. DNAhyperploidyin
exfoliated urinarybladder cellswas evaluated as amarker
for biological response to exposure of the bladder in
workers at high risk of exposure to various carcinogenic
aromatic amines,primarily2-naphthylamine (52).Thepre-
valence ofDNAhyperploidywas significantlyelevatedin a
dose-relatedmannerwithincreasingdurationofexposure,
and it was concluded that this parameter can serve as a
marker for identification of workers at increased risk in
occupational groups exposed to bladder carcinogens.
Recently, BPDE-DNA adducts were analyzed by syn-
chronous scanningfluorescence spectrophotometry inpul-
monary alveolar macrophages obtained by bronchoalveo-
lar lavage of smokers, ex-smokers, and nonsmokers, with
the objective of evaluating these cells as surrogates for
target cells at risk for lung cancer in smokers (53). The
results were interpreted to indicate that detection of
BPDE-DNA adducts in alveolar macrophages, compared
to other cell populations, was a sensitive, specific bio-
monitoring tool for assessing the internal dose ofinhaled
benzo[a]pyrene in the proximity of target cells of the
respiratorytract. Becauseinterindividualvariations inthe
activities of DNA repair enzymes may be risk factors in
the pathogenesis of lung diseases, the activities of 06_
methylguanine-DNA methyltransferase and uracil DNA
glycosylase were measured in bronchoalveolar cells and
peripheral WBC from healthy smoking and nonsmoking
men (54). Wide interindividual variation was found in both
enzyme activities, for which cigarette smoking was not
entirely responsible. 32P-Postlabeling analysis of urinary
mutagens from smokers of black tobacco has implicated
the heterocyclic amine 2-amino-1-methyl-6-phenylimi-
dazo[4,5]pyridine as a major DNA damaging agent (55).
These findings were obtained by analysis of DNA
adducted invitrobymutagens extracted fromtheurine of
smokers in the presence of a metabolic activating system;
and they extend the previous findings, described earlier,
thatindicatetheadditionalimportanceof4-aminobiphenyl
as a risk factor in smokers ofblack tobacco.
Placenta, a readily available organ that responds to
environmental exposures, has also been studied in several
investigations as a surrogate tissue for biomonitoring of
DNA adduct formation. BPDE-DNA adducts have been
detected in a large proportion of placentas analyzed by
HPLC in conjunction with synchronous scanning fluores-
cence spectrophotometry (56), additional information
about the nature and extent of PAH-DNA damage was
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obtained by immunoaffinity chromatography and 32p-
postlabeling (57,58). Comparable results were obtained in
another study in which placental DNA wvas analyzed by
32P-postlabeling and immunoassay. A positive dose-
response relationship was found among smokers between
levels of the smoking-related adducts and biochemical
estimates of doses of maternal exposure to cigarette
smoke during pregnancy (59). Carcinogen adducts have
also been analyzed by ELISA in DNA isolated from fetal
tissue and placentas from spontaneous abortions (60).
PAH-derived adducts arising from sources other than
cigarette smoke were found in a high proportion of fetal
liverand lungsamples; however, placentawas found notto
be agood surrogate forfetal tissueswNithregard to adduct
formation.
Multiple Exposure Markers in
Relation to Cancer Risk
Fewofthe above studies incorporated the simultaneous
use ofmultiple markers of exposure and biological effect
for investigation of defined populations known to be at
different levels of risk for a specific form of cancer. Such
investigations will be imperative for advancement of the
validation of molecular epidemiology as a predictive tool.
Recent results ofa series ofinvestigations in smokers are
therefore of particular importance and interest. In
smokers ofblond and black tobacco, previously shown to
be at different levels of risk for bladder cancer (61,62),
DNAadductsweremeasuredinexfoliatedurinarybladder
epithelial cells by 32P-postlabeling, Hb was analyzed for
4-aminobiphenyl adducts, and urine mutagenicity was
determined (63). At least 4 of 12 DNA adducts detected
appeared to be related to cigarette smoking, at levels two
to nine times higher in smokers than in nonsmokers. Two
DNAadducts were qualitatively similar to those observed
in an earlier study of bladder biopsies, and one of these
corresponded to N-(deoxyguanosin-8-yl)-4-aminobi-
phenyl.Thelevelsofthetwo DNAadductswerecorrelated
significantlywith the levels of4-aminobiphenyl adducts in
Hbandwiththetypeandnumberofcigarettes smoked. In
addition, levels of the putative 4-aminobiphenyl-DNA
adduct were correlated with the mutagenic activity ofthe
individual's urine. These combined data indicate the value
ofbiomarkers applied in a noninvasive biomonitoring pro-
cedure in the molecular epidemiology ofa specific form of
cancer.
Markers of Oncogene Activation and
Tumor-Suppressor Gene Inactivation
Development of malignancy is generally believed to
involve multiple steps, in which cells acquire a series of
genetic changes leading to progressive disruption of con-
trol mechanisms governing cell growth. Intensive re-
searcheffortscontinuetobedirectedtowardelucidationof
the series ofevents through which normal cells acquire a
malignant phenotype. Accumulating evidence suggests
that cancers of different origins may share certain com-
monmechanismsinvolvingactivation ofpositivelyregulat-
ing factors (oncogenes) and loss or inactivation of sup-
pressor genes, even though the precise molecular
mechanisms leading to development of specific tumor
types may differ. Cellular proto-oncogenes can be acti-
vated through severalmechanisms, includingmutations or
otherchromosomalstructural changes, such as transloca-
tions, overexpression of normal or mutated proto-
oncogenes, andamplification ofproto-oncogene sequences.
The development ofrapid assay procedures for detecting
ras mutations has led to the accumulation of a larger
amount ofinformation about the presence of these muta-
tions in tumors than exists for any other genetic change.
Much evidence has accumulated concerning the impor-
tance of ras genes in human cancers (64) and of ras
oncogene activation in tumors induced experimentally in
animals. Analysis of many activated ras genes isolated
from tumor DNA or obtained through experimental
manipulation of normal genes has revealed that they can
be activated in two ways: through point mutations or by
enhanced expression. All mutations identified to datewith
thesemethods arelocatedinthecodonsforamino acids12,
13, or 61 ofthe three ras genes. ras Gene mutations have
been found in a variety of human tumor types, although
the incidence varies greatly. The highest incidences are
foundin adenocarcinomas ofthepancreas (90%), the colon
(50%), andthelung(30%); inthyroid tumors (50%); andin
myeloid leukemia (30%). In contrast, they seem rarely to
appear in tumors of neuroectodermal origin, differenti-
ated lymphoid malignancies, or adenocarcinomas of the
breast. An interesting and important aspect of ras gene
mutations in human tumors is that they might have been
induced bycarcinogenic agents. Thisimplies thatthe type
ofmutationsfoundmayprovideinformationaboutthetype
ofmutagen involved in the induction ofthe mutation, and
therefore intheinduction ofthe tumor.Thisisparticularly
relevant in cases when speciflc mutagens are already
suspected ofplaying a role in the etiology of a particular
cancer type, orwhen clear differences in mutational spec-
traareobserved, asforexample,inpatientsfromdifferent
geographic regions. It is important in this context that
cells in an end-stage tumor containing a ras mutation are
selected, andthereforethetypeofmutation inthemis also
selected. This selection can be cell-type specific, and
tissue-specific susceptibility for a particular mutagen as
well as specificity of DNA damage and repair may influ-
ence the mutational spectrum observed in tumors. These
factors underscore the importance of developing and
applyinganalyticalprocedures ofsufficientsensitivityand
specificity to detect and quantifymutations in the earliest
stages oftumorigenesisto makepossible accurate assess-
ment ofthe significance of environmental carcinogens as
human cancerriskfactors.
Activation of ras proto-oncogenes by point mutations
has also been demonstrated in many types of tumors
induced experimentally in animals by chemical carcino-
gens. Thmors ofseveral tissues induced experimentally in
mice byvarious chemical carcinogens have been analyzed
for activated oncogenes (65). These include papilloma and
carcinoma of the skin, fibrosarcoma, mammary car-
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cinoma, lung carcinoma, T lymphoma, and hepatocellular
tumors (adenoma and carcinoma). Thoseinthe ratinclude
mammarycarcinoma, fibrosarcoma, lungcarcinoma,renal
carcinoma, neuroblastoma, glioblastoma, schwannoma,
and hepatocellular carcinoma. Severalinterestingcorrela-
tions have been drawn on the basis of information cur-
rently available. Most systems have a remarkable
specificityforaparticularoncogene-usually onemember
of the ras family. Activation of Ha-ras occurred with the
highest frequency, followed by Ki-ras. There is a striking
correlation between the tissue type affected in the tumors
andtheoncogeneactivated. Inallepithelial tumorsinmice
(skin, mammary gland, and liver), Ha-ras is activated;
whileinmesenchymaltumors(lymphomas,fibrosarcomas,
and renal), either Ki- or N-ras is activated. This preferen-
tial selection maybe related to more prevalent expression
of specific members of the ras family. With respect to
correlations between the carcinogen used and the muta-
tion found in the activated oncogene, the number ofmodel
systems studied is still too small and their characteristics
too varied to support definitive conclusions; however, of
the six possible base substitution mutations (including
mutations in both DNA strands), four have already been
found in one or more experimental systems. The B6C3F1
mouse hybrid strain has been used extensively for bio-
assays of chemicals for carcinogenic activity. Analysis of
Ha-ras oncogenesinlivertumorsinducedintheseanimals
by lifetime feeding of carcinogens of diverse structural
types revealed that the patterns of activating mutations
specific for each carcinogen were consistent with the
interpretation that they arose from direct interaction of
the activated carcinogen with the Ha-ras gene. Thus, an
extensive database supports the significance ofras genes
activated by point mutations in the development of both
human and experimentally induced tumors. It remains to
be determined whether these mutations represent early
initiating events in tumorigenesis or play a role at later
stages ofthe process. In either case, many lines ofavail-
ableevidenceindicatethatrasmutationsinthemselves are
not sufficient to produce fully developed malignant tu-
mors.Asnotedabove,developmentofmalignancyisgener-
ally believed to involve multiple steps, in which cells
acquire a series ofgenetic changes leading to progressive
disruption of the control mechanisms governing cell
growth.
In this context, information concerning the p53 gene in
the development ofhuman tumorsis alsoverypertinentin
the context of molecular epidemiology (66,67); this is
discussed in detail elsewhere in this volume. Although the
cellularp53genewasoriginallythoughttobeanoncogene,
morerecentevidenceindicatesthatthenormal (i.e., unmu-
tated) gene product actually functions as a tumor sup-
pressor. A high prevalence (75%) ofallelic deletion ofthe
p53 gene, coupled with mutational inactivation of the
remaining allele, has been observed in colorectal cancers,
and loss ofp53 function in a majority ofhuman osteosar-
comas has been correlated with gross structural rear-
rangements in the p53 gene. Allelic deletion of the
chromosome 17 region harboring the p53 gene has also
been reported in many other cancers, including those of
the lung (60%), breast, ovary, cervix, adrenal cortex, bone,
bladder, and brain. Thus, current evidence indicates that
mutations in the evolutionarily conserved codons of the
p53 tumor-suppressor gene are common in diverse types
ofhuman cancer. The p53 mutational spectrum differs in
cancers ofthe colon, lung, esophagus, breast, liver, brain,
reticuloendothelial tissues, and hematopoietic tissues.
Analysis of these mutations can provide clues to the
etiology of these diverse tumors. Transition mutations
predominate in colon, brain, and lymphoid malignancies,
whereas G-C to T-Atransversions are the most frequent
substitutions observed in the lung and liver. Mutations at
A-T base pairs are seen more frequently in esophageal
carcinomas thanin other solid tumors. Mosttransitions in
colorectal carcinomas, brain tumors, leukemias, and lym-
phomas are atCpG dinucleotide mutational hot spots. G to
Ttransversions are dispersed amongnumerous codons. In
livertumorsinpeoplefromgeographicareasinwhichboth
aflatoxin B1 and hepatitis B virus are cancer risk factors,
mostmutations are G-C to T-Atransversions atthe third
nucleotidepairofcodon249. Thesedifferencesmayreflect
the etiological contributions of both exogenous and
endogenous factors to human carcinogenesis (66).
The identification ofmutated ras and p53 genes in end-
stage tumors and the availability of sensitive analytical
procedures for their detection provide avenues for the
possible development of biomarkers for the presence of
these genetic lesions in preclinical disease states. Lung
tumors from smokers provide a unique opportunity for
investigating oncogene activation in a human tumor
believed to beinitiated bychemical carcinogens intobacco
smoke. A recent investigation of activated proto-onco-
genes in lungtumors from smokers revealed the presence
of activated oncogenenes in 86% (10/12) of DNA samples
from smokers, 8/10 of which contained mutated ras
oncogenes, which appear to play a role in metastasis in
pulmonary adenocarcinomas (68). In a second investiga-
tion ofpossible relationships between exposure to tobacco
smoke and presence ofras mutations, more mutations (all
in codon 12 of K-ras oncogenes) were found in adenocar-
cinomas from smokers (8/27) than in tumors from non-
smokers (2/27) (69). These results suggest that exposure
to carcinogens in tobacco smoke may be an important
factor in the induction of point mutations in the K-ras
oncogene in these tumors. A high frequency (35%) of
mutations in codons 12 and 61 ofthe H-ras oncogene has
also been detected in human oral carcinomas related to
tobacco chewing in India (70).
Mutations in thep53 gene have recentlybeen identified
in 11 of18 bladder tumors, and also in cells ofthe urinary
sediment in each of three patients tested (71). The p53
mutations were the first genetic alterations demonstrated
to occur in a high proportion ofprimary invasive bladder
cancers, and detection of this mutation in exfoliated cells
indicates a possible biomonitoring strategy for early
detection ofthe genetic damage.
Detection in serum ofoncogene proteins has been used
as a biomarker in the molecular epidemiology of occupa-
tional carcinogenesis (72). The ras oncogene-encoded p21
protein has been used as a prototype, since it is known to
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be activated by occupational carcinogens, is frequently
found in human tumors of occupational concern, and
appears to be expressed early in the disease process, at
least in certain instances, allowing the possibility ofearly
detection and intervention.
Mutations Observed in Vivo
in Humans
Methods have been developed forthe detection ofmuta-
tions at several selected loci in human WBC and erythro-
cytes, as discussed in detail elsewhere in this volume (73).
Measurements ofmutation frequency at the hprt locus in
cultured T lymphocytes have been particularly informa-
tive in this regard, and a significant body of data has
accumulated aboutthefrequencyofbackgroundmutations
and induced mutations under avariety ofexposure condi-
tions. Studies ofmutation frequency in patients undergo-
ing chemotherapy or radiation have been particularly
informative, and several can serve for illustrative pur-
poses. hprt Mutations were measured in a prospective
study ofmultiple sclerosis patients receiving intravenous
infusions of cyclophosphamide, a known mutagen (74).
Variant frequencies were measured in T cells cultured
from blood samples collected at intervals after initial
treatment. Two weeks after the first infusion of
cyclophosphamide, the variant frequencies were signifi-
cantly increased, but by 4 weeks they had returned to
pretreatment levels. Subsequent treatments produced
similar transient increases, butby 7-13 weeks after treat-
ment the variant frequencies ofall patients had returned
to pretreatment levels. The transient nature of the
response suggested selection in vivo against cyclophos-
phamide-induced thioguanine-resistant cells. A similar
design was used to determine the time course of
appearance andpersistence ofelevatedfrequencies ofhprt
variants in cancer patients treated with X-irradiation
therapy (75). Twelve patients treated with 180-200 cGy/
day, 5 days/week for 3-7 weeks were studied. During the
third and fourth weeks of treatment, there was a signifi-
cant (5- to 15-fold) elevation of variant frequency in all
patients, and by 6-37 weeks after treatment variant fre-
quencies had fallen to near pretreatment levels, showing a
similar transience in the induced mutation frequency, as
observed intheprevious study. Inthe contextofuseofthis
parameter as a biomarker of genotoxic exposures, the
transient nature of the response as well as its dose-
response characteristics emphasize the importance of
careful selection of sampling times following exposure.
Research is also in progress to determine whether the
spectrum ofmutations induced at the hprt locus in human
T cells can be used to identify the nature ofthe mutagens
responsible for their induction. Currently available data,
which arebeingconsolidated in arepository atthe Univer-
sity of North Carolina, will be of particular value in this
regard. The nature of these data, kindly provided by T.
Skopek (personal communication) can be summarized as
follows. In the combined in-vitro-in-vivo database, base
substitution mutations have been identified at 193 sites (of
atotal of657); atotalof257mutationshavebeenobserved,
of which 87% were missense, 11% nonsense, and 2%
involved no amino acid change. At the eight CpG sites in
the gene, six G-C to A-T transition mutations were
located atposition151,andnineatpositions501-509. Base-
substitution mutations have been observed in vivo in
healthy subjects (58 sites), in Lesch-Nyhan patients (47
sites), and in people with low exposure (smokers with
background mutant frequencies; 86 sites). Although lim-
ited overlapwas observed in the sites ofmutation between
thethree groups, thepreponderance ofmutationswere G-
C to A-T transitions or G-C to T-A transversions, the
distribution ofwhich suggests the presence ofmutational
"hot spots" in the gene. Collectively, the data suggest that
the hprt locus has the potential to serve as a sensitive
detector of base-substitution mutations in humans (T.
Skopek, personal communication).
Studies ofthe effects ofchemotherapeutic agents onthe
frequency ofglycophorin A"null" varianterythrocytes in
vivoarealsoofinterestinthiscontext(76).Anassaybased
on the enumeration of variant erythrocytes lacking
expression ofan allelic form ofglycophorin Awas used to
study blood samples from patients obtained prior to, dur-
ing, and following chemotherapy for malignant disease.
With certain therapeutic regimens, the variant frequen-
cies gradually rose during therapy, reached a maximum
(2-to7-foldhigherthannormal) atorshortlyafterthe end
oftherapy, then declined to pretherapy levels duringearly
posttherapy, with a further decline to normal within six
months. Previous investigations utilizing the same assay
showed an increased frequencyofvarianterythrocytes in
vivo in survivors ofthe atomicbombings in Hiroshimaand
Nagasaki, as well as in smokers.
The observation of ras mutations in WBC of patients
following cytotoxic therapy for lymphoma is ofparticular
relevance to molecular epidemiology (77). The occurrence
ofmyelodysplastic syndrome and acute myeloblastic leu-
kemiafollowingcytotoxic therapyfor canceriswell recog-
nized, and ras mutations are commonly observed in
patients with these diseases. To determine whether these
mutations could be used as early markers of secondary
disease, the incidence ofras mutations was determined in
WBC of patients in' complete remission from lymphoma
who had been treated with standard regimens of chem-
otherapy or combined chemo-radiotherapy. DNA from
peripheral WBC was analyzed for mutations in the three
members of the ras gene family following polymerase
chain reaction (PCR) amplification. Mutations were found
in 9 of 70 patients who had received no treatment for 6
months to 14.5 years, and who showed no sign ofresidual
disease. All patients were hematologically normal at the
time of analysis, indicating that clones of mutant ras-
bearing cells may be detected prior to any overt sign of
disease. These findings indicate the power of PCR-DNA
amplification for the detection ofsite-specific mutations in
functionally important genes, and also offer promise for
the development ofadditional, informative, early-response
biomarkers based on similar analytical approaches.
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Research Needs and Avenues for
Future Development
The foregoing summary indicates that the molecular
epidemiology of cancer is a research domain of consider-
able promise; however, the field is still at a relatively early
stage of development, and the promise remains largely
unfulfilled. While substantial progress has been made in
certain areas, especially in the development oflaboratory
analytical procedures for biomarkers of several types,
furtherimprovements are still needed in ordertofacilitate
their ready incorporation into the design ofepidemiologic
studies of cancer risks. With respect to analytical
methods, improvements in accuracy, reliability, and inter-
pretability (i.e., validation in experimental models) are
riequired. Modifications ofmethods to reduce costs will be
crucial to their use in large-scale population studies. Well-
designed studies ofpopulations ofnormal individuals will
be required to characterize the distributions ofmarkers in
different age and sex groups. Similarly, intraindividual
variability with respect to tissue localization and per-
sistence of markers, as well as interindividual variability
in genetic and acquired susceptibility factors must be
characterized to make possible valid interpretations of
data generated through molecular epidemiologic studies.
Increasing applications ofsuch biomarkers will also raise
serious bioethical issues that will need to be addressed.
Some specific avenues ofresearch that would facilitate
progress canbeidentified. Existinganalyticalmethodsfor
DNA and protein adduct measurements, should be modi-
fied, when possible, to reduce their costs and thereby
increase their applicability. In their current form, most
methods are too complex, labor intensive, and costly to
permittheiruse inpopulation-based investigations. Devel-
opment ofnew approaches ofgreater sensitivity and spe-
cificity can also be contemplated: for example, the use of
accelerator MS for the detection of DNA adducts (78).
Generic methods for detecting DNA adducts would also
greatly facilitate progress in this area, inasmuch as cur-
rent methods tend to be adduct specific or group specific,
requiringanalysis on anadduct-by-adduct basis. Anexam-
ple ofsuch a method, based on application ofthe UvrABC
DNArepair system, has been suggested (79). Inthe arena
of markers of genetic damage, dramatic advances are
being made in DNA diagnostics, combining molecular
techniques and automation (80). Applications of the PCR
amplification of DNA have led to the development of
analytical procedures for detecting sequence changes in
DNA wvith very high sensitivity and specificity. When
coupledwith radioisotopic, enzyme orfluorophore labeling
of oligonucleotides, or with denaturing gradient gel elec-
trophoresis, PCR-based analysis has been shown to be
capable ofdetectingmutations atlevels approaching back-
groundfrequencies [seeforexampleKeohavongetal. (81)].
Furthermore, one such procedure, PCR with oligonucleo-
tide ligation, has recently been fully automated (82).
Importantly, manyofthesemethods canbe applied forthe
analysis of archival pathologic tissue specimens, making
possible retrospective studies based on such material.
Many ofthese methods havebeen developed in connection
with the human genome sequencingprogram, and further
rapid progress can be anticipated. Incorporation ofthese
advances into the development ofnewbiomarkers ofearly
response and disease, as they become available, will
greatly facilitate progress ofthe field.
In addition to methodologic advances, opportunities for
further advancement require increased collaborative
research efforts, involving the active participation of spe-
cialists inepidemiologytogetherwithlaboratory scientists
in the design, execution, and interpretation of studies of
cancerrisks. Ofperhapsgreaterimportanceforthelonger
term is the cross-disciplinary training of molecular epi-
demiologists, who mustbe educated at a professional level
in the necessary aspects of basic science and also in
epidemiology. Developmentofacadre ofinvestigatorswith
this trainingwill be necessaryfor molecular epidemiology
to fulfill its promise to improve identification of cancer
risks and implementation ofpreventive strategies.
This manuscript was presented at the Conference on Biomonitolring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
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